Aptose Biosciences Inc (APS.TO) remains steady amidst significant developments in its acquisition by Hanmi Pharmaceutical.
This week, Aptose's stock price held steady at C$2.40, showing no change over the past day, week, or month. The company continues to navigate its acquisition by Hanmi Pharmaceutical while presenting clinical data that may impact its future trajectory.
Investor takeaway: Aptose's recent acquisition by Hanmi Pharmaceutical and ongoing clinical trials may present both opportunities and risks for investors. The stock's stability reflects cautious market sentiment amidst these developments.
Advertisement
Aptose Biosciences Inc
APS.TO
APS.TO
Aptose Biosciences Inc
WealthAwesomeAdvertisement
Market cap
$6.13M
52W high
$2.59
52W low
$1.41
1W change
+0.00%
Beta
0.34
Analyst Price Targets
Based on analyst covering APS
Wall Street analysts forecast APS stock price to fall 1.7% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.36
-1.7% Upside
Current Price
C$2.40
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APS's historical volatility
30-Day Vol
52.7%
Annualized
90-Day Vol
48.9%
Annualized
Trend (90d)
-0.0%
Annualized drift
90d Mean
C$2.40
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.40 | C$2.00 – C$2.88 |
| 60 trading days | C$2.40 | C$1.86 – C$3.10 |
| 90 trading days | C$2.40 | C$1.75 – C$3.29 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Aptose Biosciences Inc maintains a steady stock price of C$2.40.
The stock has shown an 18.81% increase year-to-date, reflecting some investor optimism despite recent operational challenges.
Bull case
With the acquisition by Hanmi Pharmaceutical now complete, Aptose could gain enhanced resources and strategic direction. This support may benefit its clinical programs and improve its overall position in the market.
Bear case
However, the company's current financial metrics raise concerns. With a negative return on equity and a profit margin of 0.0%, there are worries about its operational efficiency and long-term profitability, which could deter potential investors.
Recent Stock Performance
Aptose's stock closed at C$2.40, with no significant movement over the past day or week. Year-to-date, the stock has appreciated by 18.81%. The trading volume was 2,945 shares, slightly below the 20-day average volume of 3,425 shares, indicating lower trading activity compared to recent weeks.
Company Developments
Advertisement
Recent headlines indicate that Aptose has completed its acquisition by Hanmi Pharmaceutical, a milestone that could reshape its strategic direction. The company also presented clinical data at the 2026 EHA Congress, focusing on its TUSCANY Phase 1/2 trial for acute myeloid leukemia. These developments are crucial as they may influence investor sentiment and future stock performance.
Technical Picture
From a technical standpoint, Aptose is currently trading above its 50-day moving average of C$2.25 and its 200-day moving average of C$2.14, suggesting a positive short-term outlook. The stock's 52-week range is C$1.41 – C$2.59, indicating it is currently trading at approximately 84% of its highest price in the past year. The stock's beta of 0.34 suggests lower volatility compared to the market.
Fundamentals Overview
Aptose has a market capitalization of approximately C$6.13 million. However, its profit margin stands at 0.0%, and it has a negative return on equity of -694.1%, raising concerns about its financial health. The earnings per share (EPS) stands at -14.78, indicating ongoing operational challenges that investors should consider.
Price Action Summary
Aptose's stock closed at C$2.40, reflecting no change in price over the past day. Investors will be keen to monitor the impacts of the recent acquisition and clinical data presentations on future stock performance.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
